Seven Eight Capital’s BridgeBio Pharma BBIO Stock Holding History

Seven Eight Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-199,934	Closed	-$5.09M	–	66
2024 Q3	$5.09M	Buy	+199,934	New	+$5.25M	0.46%	29
2022 Q1	–	Sell	-213,121	Closed	-$3.56M	–	525
2021 Q4	$3.56M	Buy	+213,121	New	+$9.02M	0.64%	31

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Seven Eight Capital's BBIO Position: Q4 2024 in Review

Seven Eight Capital sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 199,934 shares — an estimated $5.09M sold.

Seven Eight Capital first reported a position in BBIO in Q4 2021 and held it in 2 quarters. The position peaked at $5.09M in Q3 2024. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

Seven Eight Capital reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
Seven Eight Capital sold 199,934 BridgeBio Pharma shares in Q4 2024, an estimated $5.09M.
Seven Eight Capital first reported a position in BridgeBio Pharma in Q4 2021 and held it in 2 quarters.
Seven Eight Capital's BridgeBio Pharma position peaked at $5.09M in Q3 2024.
263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.